Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03462459
Other study ID # 2017-0927
Secondary ID 1R01HS025713-01A
Status Completed
Phase Phase 2
First received
Last updated
Start date May 21, 2018
Est. completion date July 6, 2023

Study information

Verified date July 2023
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.


Description:

Many patients who have a CDI experience recurrent or relapsing symptoms. The investigators are studying whether vancomycin in low doses will help prevent further CDI episodes and how this therapy impacts patients' gastrointestinal microbiome and composition. Patients with a history of past CDI who are receiving antibiotics for a non-CDI condition will be invited to participate. Approximately half of the participants will receive a low-dose capsule of vancomycin and half will receive a placebo. Participants will continue taking the vancomycin/placebo for 5 days after their prescribed antibiotics end.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date July 6, 2023
Est. primary completion date July 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing to provide informed consent. - Willing to comply with all study procedures and be available for the duration of the study. - Documented diagnosis of at least one CDI within the last 180 days with treatment completed. - Currently receiving systemic antibiotics for a non-CDI condition with anticipated duration of no more than 2 weeks. - Females of childbearing potential must have a negative pregnancy test prior to randomization and agree to use adequate contraception prior to randomization, for the duration of the study, and for 4 weeks following study completion. - Have received no more than 72 hours of non-CDI antibiotics. Exclusion Criteria: - History of hypersensitivity or allergy to oral vancomycin. - Current use of oral vancomycin - Patients on concurrent treatment with metronidazole or tetracycline monotherapy for any indication - Patients diagnosed with inflammatory bowel disorder (Crohn's disease), or bacterial gastrointestinal infection cause by agents other than C. difficile (e.g. Salmonella sp.), toxic megacolon and/or known small bowel ileus. - Dysphagia (inability to swallow capsules) or unwilling to swallow capsules. - Major gastrointestinal surgery within 3 months of enrollment (does not include appendectomy or cholecystectomy). - Any history of total colectomy or bariatric surgery. - Unable or unwilling to fulfill study requirements. - Expected life expectancy < 6 months. - Patients enrolled in another clinical trial with investigational drugs within 30 days prior to randomization. - Women who are pregnant or breast-feeding. - Any patient deemed not suitable for study participation at the discretion of the study investigator. - Diarrhea (3 or more loose stools in a 24 hour period) at enrollment.

Study Design


Intervention

Drug:
Vancomycin
Vancomycin capsule, 125 mg
Placebo
Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule

Locations

Country Name City State
United States University of Wisconsin-Madison Madison Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin

Sponsors (5)

Lead Sponsor Collaborator
University of Wisconsin, Madison Agency for Healthcare Research and Quality (AHRQ), Henry Ford Hospital, Mayo Clinic, Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrent Clostridium difficile infection (CDI) Determine whether CDI recurrence is decreased in patients taking oral vancomycin as prophylactic therapy in addition to standard-of-care antibiotics that patients are taking for non-CDI reasons. 8 weeks
Secondary Gut microbiome composition Study how the gut microbiome is altered in patients receiving vancomycin treatment compared to placebo. 8 weeks
Secondary Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo Low-dose exposure to vancomycin and VRE infection has not been studied. We will examine the incidence of VRE colonization in all patients and determine whether oral vancomycin increases the VRE colonization rate. 8 weeks
Secondary Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence. Stool samples will be tested at baseline, at the last dose date of vancomycin or placebo, at approximately 8 weeks following the last dose of vancomycin or placebo, and as indicated for diarrhea symptoms. Samples will be collected and tested for the presence of Clostridium difficile. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02214771 - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients N/A
Withdrawn NCT01552668 - Fidaxomicin to Prevent Clostridium Difficile Colonization Phase 4
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Not yet recruiting NCT03586206 - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended NCT03350711 - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn NCT03643887 - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients Phase 2
Terminated NCT04000555 - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Phase 4
Terminated NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 Phase 1/Phase 2
Completed NCT03710694 - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) N/A
Completed NCT02865616 - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) Phase 1
Recruiting NCT04940468 - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology N/A
Completed NCT02589847 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection Phase 2
Not yet recruiting NCT01942447 - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis N/A
Active, not recruiting NCT02086916 - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection N/A
Completed NCT01230957 - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults Phase 2
Completed NCT01241552 - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) Phase 3
Not yet recruiting NCT04567134 - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed NCT04075422 - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting NCT03712722 - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting NCT05192148 - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile N/A